Aytu BioPharma (AYTU) Financials

Aytu BioPharma’s latest quarter showed a sharp improvement in operating performance, but the company remains financially dependent on working-capital movements and financing activity. Revenue increased to $16.1 million in Q4 2026 from $12.4 million in Q3, while gross profit rose to $10.4 million. The gross margin was approximately 64.6%, up from 61.2% in the prior quarter and broadly consistent with the company’s recent range.

Operating results also improved meaningfully. The operating loss narrowed to $777,000 from $4.1 million in Q3, helped by lower selling, general and administrative expense and slightly lower marketing expense relative to revenue. However, operating expenses of $11.2 million still exceeded gross profit, and the company has not established a consistent pattern of operating profitability across the reported periods.

Net results were close to breakeven, with a reported net loss of only $15,000 in Q4 compared with a $5.6 million loss in Q3 and a $10.6 million loss in Q2. The improvement was supported by $1.2 million of other income, which more than offset $383,000 of interest expense. Investors should note that the reported Q4 basic EPS of $0.21 does not appear consistent with the reported net loss and share count, so the per-share data should be treated cautiously until reconciled with the company’s filing.

Cash flow improved substantially in Q4. Operating cash flow was $4.4 million, reversing the $4.2 million operating cash outflow in Q3. Most of the improvement came from a $3.7 million favorable change in operating assets and liabilities, rather than from sustained earnings. After a modest $12,000 investment in property and equipment and a $4.8 million financing cash outflow, cash declined by $407,000 for the quarter.

The latest available balance sheet, as of March 31, 2026, showed $26.7 million of cash and equivalents, $67.3 million of current assets and $60.0 million of current liabilities. That represents a current ratio of approximately 1.1, leaving limited short-term liquidity cushion. Total liabilities of $76.5 million exceeded shareholders’ equity of $35.1 million, while retained earnings remained deeply negative at $347.8 million.

• Revenue momentum improved: Q4 revenue rose approximately 30% sequentially to $16.1 million and was 6% above Q4 2025 revenue.
• Gross profitability remained solid: Gross profit reached $10.4 million, with a quarterly gross margin of about 64.6%.
• Operating losses narrowed: The operating deficit improved from $4.1 million in Q3 to $777,000 in Q4.
• Operating cash flow turned positive: Q4 operating cash flow of $4.4 million was a significant improvement from the $4.2 million outflow in Q3.
• Reported net losses have narrowed sharply: The Q4 net loss of $15,000 was substantially better than the losses reported in the prior two quarters.
• Working capital was a major cash-flow driver: The Q4 operating cash benefit primarily reflected changes in operating assets and liabilities, which may not be repeatable.
• Asset quality requires monitoring: Intangible assets totaled $42.5 million, representing a large portion of the company’s $111.7 million in total assets.
• Profitability remains inconsistent: A history of operating losses and negative net income in several recent quarters indicates that the business has not yet demonstrated durable earnings power.
• Liquidity is relatively tight: Current liabilities of $60.0 million were close to current assets of $67.3 million, while cash declined in the latest quarter.
• Leverage and financing needs remain risks: A $4.8 million financing cash outflow in Q4, substantial debt balances and deeply negative retained earnings could require additional borrowing or equity financing.